Kuros Biosciences AG (FRA:YTSN)

Germany flag Germany · Delayed Price · Currency is EUR
23.40
-0.02 (-0.09%)
Last updated: May 22, 2026, 8:03 AM CET
Market Cap935.30M -16.2%
Revenue (ttm)124.40M +71.5%
Net Income2.17M
EPS0.05
Shares Outn/a
PE Ratio430.48
Forward PE86.83
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open23.40
Previous Close23.42
Day's Range23.40 - 23.40
52-Week Range20.12 - 35.32
Betan/a
RSI52.43
Earnings DateAug 13, 2026

About Kuros Biosciences AG

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone graft... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Employees 178
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol YTSN

Financial Performance

Financial numbers in USD Financial Statements

News

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

17 days ago - GlobeNewsWire

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total product ...

5 weeks ago - GlobeNewsWire

Kuros Biosciences AG Earnings release: Q1 2026

Kuros Biosciences AG released its Q1 2026 earnings on April 14, 2026, summarizing the period's financial results.

5 weeks ago - Filings

Kuros Biosciences AG Earnings release: Q1 2026

Kuros Biosciences AG released its Q1 2026 earnings on April 14, 2026, summarizing the period's financial results.

5 weeks ago - Filings

Kuros Biosciences AG Earnings Call Transcript: H2 2025

Achieved first-time profitability in 2025 with 72% revenue growth and strong operational execution. Guidance for 2026 targets at least 35% revenue growth and 14% adjusted EBITDA margin, with continued expansion in spine, extremities, and trauma segments.

2 months ago - Transcripts

Kuros Biosciences AG Earnings release: H2 2025

Kuros Biosciences AG released its H2 2025 earnings on March 10, 2026, summarizing the period's financial results.

2 months ago - Filings

Kuros Biosciences AG Annual report: H2 2025

Kuros Biosciences AG has published its H2 2025 annual report on March 10, 2026.

2 months ago - Filings

Kuros Biosciences AG Slides: H2 2025

Kuros Biosciences AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 10, 2026.

2 months ago - Filings

Kuros Biosciences AG Earnings Call Transcript: H2 2025

Achieved first-time profitability in 2025 with 72% revenue growth and strong operational execution. Guidance for 2026 targets at least 35% revenue growth and 14% adjusted EBITDA margin, with continued expansion in spine, extremities, and trauma segments.

2 months ago - Transcripts

Kuros Biosciences AG Earnings release: H2 2025

Kuros Biosciences AG released its H2 2025 earnings on March 10, 2026, summarizing the period's financial results.

2 months ago - Filings

Kuros Biosciences AG Annual report: H2 2025

Kuros Biosciences AG has published its H2 2025 annual report on March 10, 2026.

2 months ago - Filings

Kuros Biosciences AG Slides: H2 2025

Kuros Biosciences AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 10, 2026.

2 months ago - Filings

Kuros Biosciences AG Earnings release: Q3 2025

Kuros Biosciences AG released its Q3 2025 earnings on October 16, 2025, summarizing the period's financial results.

7 months ago - Filings

Kuros Biosciences AG Earnings release: Q3 2025

Kuros Biosciences AG released its Q3 2025 earnings on October 16, 2025, summarizing the period's financial results.

7 months ago - Filings

Kuros Biosciences AG Earnings Call Transcript: H1 2025

Achieved 78% revenue growth and first operating profit in H1 2025, driven by strong execution in spine and extremities, Medtronic partnership, and new product launches. Guidance for at least 60% annual growth is maintained, with minimal tariff impact expected and U.S. production set for H2 2026.

10 months ago - Transcripts

Kuros Biosciences AG Quarterly report: H1 2025

Kuros Biosciences AG has published its H1 2025 quarterly earnings report on August 14, 2025.

10 months ago - Filings

Kuros Biosciences AG Slides: H1 2025

Kuros Biosciences AG has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 14, 2025.

10 months ago - Filings

Kuros Biosciences AG Earnings Call Transcript: H1 2025

Achieved 78% revenue growth and first operating profit in H1 2025, driven by strong execution in spine and extremities, Medtronic partnership, and new product launches. Guidance for at least 60% annual growth is maintained, with minimal tariff impact expected and U.S. production set for H2 2026.

10 months ago - Transcripts

Kuros Biosciences AG Quarterly report: H1 2025

Kuros Biosciences AG has published its H1 2025 quarterly earnings report on August 14, 2025.

10 months ago - Filings

Kuros Biosciences AG Slides: H1 2025

Kuros Biosciences AG has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 14, 2025.

10 months ago - Filings